Semaglutide: Where the Evidence Costs More Than the Claim

The short version

Semaglutide (Ozempic, Wegovy, Rybelsus) is a laboratory-modified copy of a hormone the gut releases after a meal. The natural hormone, GLP-1, tells the pancreas to release insulin, tells the stomach to empty more slowly, and tells the brain that eating is finished. It is destroyed within about two minutes. Semaglutide was engineered to survive roughly a week instead, which is why it is given once weekly rather than continuously.

What makes it interesting to this desk is not the mechanism but the receipts. Most compounds in this field are supported by laboratory work and small studies. Semaglutide is supported by trials that enrolled thousands of people, followed them for more than a year, randomly assigned half of them to a placebo, and then counted the things that actually happen to people: heart attacks, strokes, kidney failure, deaths. That is the most expensive form of evidence there is, and it is the reason this page reads differently from the other two.

What it is

Semaglutide is a 31-amino-acid acylated analogue of human glucagon-like peptide-1, sharing roughly 94% of its sequence with the natural hormone. Two deliberate substitutions in the backbone buy it durability. At position 8, alanine is swapped for alpha-aminoisobutyric acid, which blocks the enzyme dipeptidyl peptidase-4 from cutting the molecule in half. At position 34, lysine is replaced by arginine, leaving a single lysine at position 26 free for modification.

That remaining lysine carries a C18 fatty di-acid side chain attached through a spacer. The fatty tail binds reversibly and strongly to albumin, the most abundant protein in blood plasma. Bound to albumin, the peptide is shielded from filtration by the kidney and from metabolic breakdown, which is the entire structural basis for once-weekly administration.

It is classed as a glucagon-like peptide-1 receptor agonist, or incretin mimetic, and it is approved as both a once-weekly subcutaneous injection and a once-daily oral tablet. The oral form is co-formulated with an absorption enhancer and has very low oral bioavailability, which is why its administration instructions are unusually strict.

How it works

Semaglutide activates the GLP-1 receptor in several tissues at once, and the effects worth knowing are split between the pancreas and the brain.

In the pancreas, receptor activation on beta cells potentiates insulin secretion in a glucose-dependent way — meaning it amplifies insulin release when blood sugar is high and largely stands down when it is not. On alpha cells it suppresses inappropriate glucagon release. In the stomach it slows gastric emptying, which both blunts post-meal glucose spikes and produces most of the digestive side effects the compound is known for.

The weight effect, however, is primarily central. Semaglutide reaches appetite circuits in the hypothalamic arcuate nucleus and in the brainstem area postrema, where it activates the appetite-suppressing POMC and CART neurons and inhibits the appetite-driving NPY and AgRP neurons. The result is reduced food intake and a shift in food preference, without a fall in energy expenditure. GLP-1 receptors are also present in cardiovascular and renal tissue, which is the working explanation for the protective effects seen in the outcome trials below.

What the research shows

This is the section where the price of the evidence is visible.

Cardiovascular events. In a trial of 17,604 adults with established cardiovascular disease and a body-mass index of 27 or above, but without diabetes, once-weekly semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke against placebo, with a hazard ratio of 0.80 and a 95% confidence interval of 0.72 to 0.90 ^[3]. That is a 20% relative risk reduction, measured in events rather than markers.

Kidney events. In 3,533 people with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced major kidney-disease events — kidney failure, a fall in eGFR of at least 50%, or kidney or cardiovascular death — with a hazard ratio of 0.76 and a 95% confidence interval of 0.66 to 0.88 ^[2].

Weight. In a randomised trial in adults with overweight or obesity and without diabetes, participants receiving once-weekly subcutaneous semaglutide 2.4 mg had a mean body-weight change of -14.9% from baseline at week 68, against -2.4% on placebo — a treatment difference of roughly 12.4 percentage points ^[4].

Head to head. In a 751-participant trial comparing the two directly in adults with obesity, tirzepatide produced greater mean weight loss than semaglutide at 72 weeks, -20.2% against -13.7%, a difference of about 6.5 percentage points at P less than 0.001 ^[1]. This is worth flagging as a matter of evidence pricing rather than product ranking: head-to-head trials are rare and expensive, and their existence is itself a signal of how much has been invested in this class.

Safety, as reviewed. A dedicated safety review concluded that semaglutide carries an overall favourable risk-benefit profile in type 2 diabetes, with mostly mild-to-moderate transient gastrointestinal effects, nausea in roughly one-third of patients, an increased risk of biliary disease, and pancreatic and thyroid-cancer signals for which definitive conclusions cannot yet be drawn owing to low incidence ^[5].

Reported effects, cautions and safety

What follows in this first part is anecdotal, not clinical evidence — patterns drawn from what people write in public review and patient communities, with no controls, no verification, and no doses attached. It is recorded here because the pattern is consistent and because it is a useful contrast with the trial data above, not because it carries the same weight.

The benefit people describe most is a quieting of what many call food noise: the constant background preoccupation with the next meal simply going silent, often within the first weeks. Alongside it, reviewers frequently report cravings for sugar and for fried or greasy food dropping sharply, sometimes to the point of aversion. Weight loss is reported by the large majority, usually described as steady over months and slowing after an early period, and attributed by most to eating far less rather than to any change in activity. People treating type 2 diabetes commonly describe improved blood-sugar readings. A recurring secondary observation, discussed widely in patient communities, is a fading interest in alcohol.

On the adverse side the same communities report nausea most often, sometimes escalating to vomiting, peaking early and after each increase in dose. A distinctive and much-discussed complaint is foul sulfurous burping. Disrupted bowel habits are reported at both extremes, sometimes alternating. Reflux, early fatigue, headaches, taste changes and heightened smell sensitivity, mild injection-site reactions, and — among those losing weight fastest — hair shedding and facial gauntness all recur. All of that remains anecdotal, not clinical evidence.

The documented cautions are a different class of statement. Gastrointestinal intolerance during dose escalation is the dominant adverse effect in trials and the leading cause of discontinuation, and it is mechanistic rather than incidental: the slowed gastric emptying that produces it is part of how the drug works ^[5]. A boxed warning covers personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, derived from rodent C-cell tumours at supratherapeutic exposures; human data have not established a clear increase in thyroid cancer ^[5]. Acute pancreatitis is a class warning and treatment is conventionally stopped if it is suspected. Gallbladder and biliary disease are increased against placebo, attributed largely to the rate and magnitude of weight loss ^[5]. In people with pre-existing diabetic retinopathy, monitoring is advised when blood glucose is corrected rapidly ^[5]. Body-composition substudies show a meaningful fraction of the weight lost is lean mass, which raises a sarcopenia concern in older adults. Substantial weight regain follows discontinuation, which frames this as a chronic rather than curative intervention. Pregnancy is a contraindication. None of this constitutes medical advice, and nothing on this page recommends a dose to anyone.

What this evidence is worth

On the four levers this desk grades, semaglutide scores at or near the ceiling on every one. Sample sizes run into five figures. Follow-up runs into years. Randomised placebo comparison is present throughout. And the endpoints are events rather than surrogates — the primary results above are counts of heart attacks, strokes, kidney failures and deaths, not blood levels chosen because they were easy to measure ^[2][3].

That combination is what makes the semaglutide record the reference standard for the rest of this site. It sets the exchange rate. When a claim elsewhere in peptide research is described as proven, the honest question is whether it was proven at this price or at a much lower one — and in almost every case the answer is the latter.

The useful caution runs the other way. Expensive evidence is narrow evidence. Those trials answer precisely what they were designed to answer, in the populations they enrolled, at the doses and formulations they used. They do not license extrapolation to different people, different products or different routes. A finding this well-bought is worth a great deal exactly where it applies, and no more elsewhere than a cheap one.